Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies

By Roehrborn C.G.   Siegel R.L.  

Urology, Vol. 48, Iss. 3, 1996-09 ,pp. : 406-415

Elsevier

Access to resources Recommend Favorite

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia

By Elhilali M.M.   Ramsey E.W.   Barkin J.   Casey R.W.   Boake R.C.   Beland G.   Fradet Y.   Trachtenberg J.   Orovan W.L.   Schick E.   Klotz L.H.  

Urology, Vol. 47, Iss. 3, 1996-03 ,pp. : 335-342

Elsevier

Access to resources Recommend Favorite

Long-Term Evaluation of Tamsulosin in Benign Prostatic Hyperplasia: Placebo-Controlled, Double-Blind Extension of Phase III Trial - risk factors and concomitance with hypertension

By Lepor H.  

Urology, Vol. 51, Iss. 6, 1998-06 ,pp. : 901-906

Elsevier

Access to resources Recommend Favorite

Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin

By Roehrborn C.G.   Oesterling J.E.   Olson P.J.   Padley R.J.  

Urology, Vol. 50, Iss. 4, 1997-10 ,pp. : 556-561

Elsevier

Access to resources Recommend Favorite

Phase III Multicenter Placebo-Controlled Study of Tamsulosin in Benign Prostatic Hyperplasia - a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH)

By Lepor H.  

Urology, Vol. 51, Iss. 6, 1998-06 ,pp. : 892-900

Elsevier

Access to resources Recommend Favorite